A pharmacological model of SLOS has been generated by systemic treatment of rats with AY9944 [(trans-1,4-bis(2-dichlorobenzylamino-ethyl)) cyclohexane dihydrochloride], a DHCR7 inhibitor (76). Here, DHCR7 is linked to Smith-Lemli-Opitz syndrome.